Santen Pharmaceutical

Eyevance is a provider of ophthalmic products and therapies intended to address unmet medical needs. The company's products target areas such as the anterior segment, posterior segment and glaucoma ailments, providing patients with optimal vision and a better quality of life.

Plano was developed with a clear purpose; to save sight and empower lives.1.5 billion people across the world currently suffer from myopia (short-sightedness). This number is expected to rise exponentially to 5 billion people by 2050, 1 billion of whom will develop high myopia which often leads to blinding eye conditions and reduced quality of life. The correlation of the onset of myopia with the rapid increase in excessive smart device use in children worldwide, is not the only adverse effect resulting from the shift in their lifestyle habits concurrent with an increasingly digitised world. The World Health Organisation (WHO) has officially classified internet addiction syndrome and gaming addiction as mental health conditions.

QD Laser is a developer of quantum dot laser technology designed to offer high performance semiconductor lasers.The company's quantum dot laser technology develops new semiconductor lasers in a wide range of fields and offer current-free quantum dot lasers for communications, enabling telecommunication industries to get services that helps them improve their businesses.

QD Laser is a developer of quantum dot laser technology designed to offer high performance semiconductor lasers.The company's quantum dot laser technology develops new semiconductor lasers in a wide range of fields and offer current-free quantum dot lasers for communications, enabling telecommunication industries to get services that helps them improve their businesses.

International Biomedical Devices (IBMD) is an early-stage medical device company focused on ophthalmology innovations. At present, the company is leading the emerging, non-laser based, precision capsulotomy category through the development of a unique and much-needed new capsulotomy technology. It was founded in 2013 and is based in Charleston, South Carolina.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

TearSolutions is a pharmaceutical company that specializes in providing medical solutions for dry eyes. The company is driven by its mission is to develop a novel replacement therapy for dry eye through phase II human clinical trials. The platform technology is centered on the remarkable tear protein and the proprietary drug 'Lacripep'. An outsourcing model will be used.

Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.

Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.